急性缺血性卒中患者接受阿替普酶治疗前使用非维生素K拮抗剂口服抗凝药的出血风险
该研究为台湾全国性人群队列研究,纳入2011年1月至2020年11月期间因急性缺血性卒中接受阿替普酶治疗的7483例患者,比较卒中前2天内使用非维生素K拮抗剂口服抗凝药(NOACs)与未使用抗凝药或使用华法林的患者。倾向性评分匹配分析显示,与未使用抗凝药相比,NOACs组颅内出血风险差异为2.47%(95%CI -4.23%至9.17%),OR 1.37(95%CI 0.62-3.03);大出血风险差异4.95%(95%CI -2.56%至12.45%),OR 1.69(95%CI 0.83-3.45);院内死亡风险差异-4.95%(95%CI -10.11%至0.22%),OR 0.45(95%CI 0.15-1.29),均无显著差异。NOACs组与华法林组出血和死亡风险亦无显著差异。荟萃分析结果相似。
要点
- 在7483例接受阿替普酶治疗的急性缺血性卒中患者中,卒中前2天内使用NOACs者占1.2%(91例),使用华法林者占2.4%(182例),未使用抗凝药者占96.4%(7210例)。
- 倾向性评分匹配后,与未使用抗凝药相比,NOACs组颅内出血风险差异2.47%(95%CI -4.23%至9.17%),OR 1.37(95%CI 0.62-3.03),无显著差异。
- NOACs组与未使用抗凝药组大出血风险差异4.95%(95%CI -2.56%至12.45%),OR 1.69(95%CI 0.83-3.45),无显著差异。
- NOACs组与未使用抗凝药组院内死亡风险差异-4.95%(95%CI -10.11%至0.22%),OR 0.45(95%CI 0.15-1.29),无显著差异。
- NOACs组与华法林组出血和死亡风险无显著差异;荟萃分析结果与队列研究相似。
适用人群与场景
- 2011年1月至2020年11月台湾全国性人群队列中因急性缺血性卒中接受静脉阿替普酶治疗的7483例患者。
- 卒中前2天内使用NOACs者91例(1.2%),使用华法林者182例(2.4%),未使用抗凝药者7210例(96.4%)。
研究设计与关键结果
- 研究类型:全国性、基于人群的队列研究(台湾全民健康保险研究数据库,2011年1月至2020年11月),并纳入前瞻性注册于PROSPERO的荟萃分析。
- 人群:7483例接受阿替普酶治疗的急性缺血性卒中患者,平均年龄67.4岁(SD 12.7),女性2908例(38.9%),男性4575例(61.1%)。
- 暴露:卒中前2天内使用NOACs,对照为未使用抗凝药或使用华法林。
- 主要终点:倾向性评分匹配后,与未使用抗凝药相比,NOACs组颅内出血风险差异2.47%(95%CI -4.23%至9.17%),OR 1.37(95%CI 0.62-3.03),无显著差异。
- 次要终点:大出血风险差异4.95%(95%CI -2.56%至12.45%),OR 1.69(95%CI 0.83-3.45);院内死亡风险差异-4.95%(95%CI -10.11%至0.22%),OR 0.45(95%CI 0.15-1.29),均无显著差异。
- NOACs组与华法林组出血和死亡风险无显著差异;荟萃分析(随机效应模型)结果相似。
证据类型、等级与局限
- 证据类型:全国性基于人群的队列研究加荟萃分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论:与未使用抗凝药相比,卒中前使用NOACs与接受静脉阿替普酶治疗的急性缺血性卒中患者颅内出血、大出血或死亡风险升高无关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Current guidelines advise against intravenous alteplase therapy for treatment of acute ischemic stroke in patients previously treated with non-vitamin K antagonist oral anticoagulants (NOACs).
OBJECTIVE: To evaluate the risk of bleeding and mortality after alteplase treatment for acute ischemic stroke among patients treated with NOACs compared to those not treated with NOACs.
DESIGN, SETTING, AND PARTICIPANTS: This nationwide, population-based cohort study was conducted in Taiwan using data from Taiwan's National Health Insurance Research Database from January 2011 through November 2020 and included 7483 patients treated with alteplase for acute ischemic stroke. A meta-analysis incorporating the results of the study with those of previous studies was performed, and the review protocol was prospectively registered with PROSPERO.
EXPOSURES: NOAC treatment within 2 days prior to stroke, compared to either no anticoagulant treatment or warfarin treatment.
MAIN OUTCOMES AND MEASURES: The primary outcome was intracranial hemorrhage after intravenous alteplase during the index hospitalization (the hospitalization subsequent to alteplase administration). Secondary outcomes were major bleeding events and mortality during the index hospitalization. Propensity score matching was used to control potential confounders. Logistic regression was used to estimate the odds ratio (OR) of outcome events. Meta-analysis was performed using a random-effects model.
RESULTS: Of the 7483 included patients (mean [SD] age, 67.4 [12.7] years; 2908 [38.9%] female individuals and 4575 [61.1%] male individuals), 91 (1.2%), 182 (2.4%), and 7210 (96.4%) received NOACs, warfarin, and no anticoagulants prior to their stroke, respectively. Compared to patients who were not treated with anticoagulants, those treated with NOACs did not have significantly higher risks of intracranial hemorrhage (risk difference [RD], 2.47% [95% CI, -4.23% to 9.17%]; OR, 1.37 [95% CI, 0.62-3.03]), major bleeding (RD, 4.95% [95% CI, -2.56% to 12.45%]; OR, 1.69 [95% CI, 0.83-3.45]), or in-hospital mortality (RD, -4.95% [95% CI, -10.11% to 0.22%]; OR, 0.45 [95% CI, 0.15-1.29]) in the propensity score-matched analyses. Furthermore, the risks of bleeding and mortality were not significantly different between patients treated with NOACs and those treated with warfarin. Similar results were obtained in the meta-analysis.
CONCLUSIONS AND RELEVANCE: In this cohort study with meta-analysis, compared to no treatment with anticoagulants, treatment with NOACs prior to stroke was not associated with a higher risk of intracranial hemorrhage, major bleeding, or mortality in patients receiving intravenous alteplase for acute ischemic stroke.
参考来源
- Tsai TY, Liu YC, Huang WT, et al. Risk of Bleeding Following Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Acute Ischemic Stroke Treated With Alteplase. JAMA Intern Med. 2024. PMID: 37983035. doi:10.1001/jamainternmed.2023.6160
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。